Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Robot vs. standard surgery: which is safer for Women's cancers?

NCT ID NCT01247779

Knowledge-focused Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 386 women with cervical, uterine, or ovarian cancer to compare standard laparoscopic surgery versus robot-assisted laparoscopic surgery. The goal was to see which approach causes fewer complications within six months after the operation. Researchers tracked side effects, pain control, and surgeon comfort to help guide future surgical choices.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors choose the safer surgical method for women with gynecologic cancers.
What could go wrong
This is an observational comparison, not a treatment test. Results may not apply to all patients or hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

386 people

The number who actually took part.

Started

Dec 2010

Finished

Nov 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patient with uterus cancer depending on hysterectomy ± pelvic lymphadenectomy or a restadification * patient with cervical cancer depending on enlarged colpo-hysterectomy ± pelvic lymphadenectomy or a surgery after concomitant radiochemotherapy, or lombo aortic lymphadenectomy for a locally advanced cancer, or a restadification * patient with cervical cancer depending on a restadification * patient aged over 18 years * previous antitumor treatment allowed but necessarily disrupted 20 days before inclusion * WHO score equal or inferior to 3 * cirrhosis-related Child-Pugh score under or equal to A7 are allowed * life expectancy equal or superior to 12 weeks * patient affiliated to health insurance * dated and signed informed consent Exclusion Criteria: * metastatic disease * pregnant or breastfeeding woman * patient unable to proceed follow-up visit, because of geographic, social or mental reasons

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical cancer neoplasm ovarian cancer uterine cancer Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical cancer Ovarian cancer Uterus cancer

Contacts and locations

Locations

  • CHRU Lille, Hôpital Jeanne de Flandres

    Lille, 59037, France

  • CHRU de Tours

    Tours, 37044, France

  • CHU Bordeaux, Hôpital Saint-André

    Bordeaux, 33300, France

  • CHU Limoges

    Limoges, 87042, France

  • CHU Nîmes

    Nîmes, 30029, France

  • CHU Rangueil

    Toulouse, 31059, France

  • Centre Alexis Vautrin

    Vandœuvre-lès-Nancy, 54511, France

  • Centre Hospitalier de Valenciennes

    Valenciennes, 59322, France

  • Centre Oscar Lambret

    Lille, 59000, France

  • Centre hospitalier de Roubaix

    Roubaix, 59056, France

  • Hôpital Européen Georges Pompidou

    Paris, 75015, France

  • Institut Claudius Regaud

    Toulouse, 31052, France

  • Institut Paoli Calmette

    Marseille, 13009, France

  • Institut de Cancérologie de l'Ouest Site René Gauducheau

    Saint-Herblain, 44805, France

  • Polyclinique Bordeaux Nord Aquitaine

    Bordeaux, 33300, France

  • Polyclinique Courlancy

    Reims, 51100, France

  • Polyclinique KenVal

    Nîmes, 30900, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.